11/03/2015 - 4:21pm

With the completion of this step all Mylan needs is word from Perrigo’s shareholders on whether or not they will accept the company’s $27 billion acquisition offer, which was tendered on Sept. 14. 

11/03/2015 - 3:30pm
Using VoicePort’s PharmaPhonetics system, the partnership is aimed at finding immunization gaps in patient records for pharmacists.
11/03/2015 - 2:57pm

Thinfilm’s NFC OpenSense tags are thin labels that can tell whether the injector has been used or not, and can send information about the injector’s state to a smartphone

11/03/2015 - 2:31pm
The Regulartory Affairs Professionals Society is reporting that as part of the recently passed budget deal that the president signed Monday, generics companies whose prices rise beyond the Average Manufacturer Price that’s adjusted for inflation will have to pay higher rebates. “The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug of a manufacturer, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased,” the act says. (RAPS)
11/03/2015 - 2:30pm

A new study by IMS Health for the Generic Pharmaceutical Association is highlighting the savings that generic drugs bring to patients. 

11/03/2015 - 2:23pm

Sun Pharmaceutical Industries has completed its acquisition of InSite Vision. 

11/03/2015 - 12:11pm

With the CCMRegistry.com Apple TV App, patients and family can securely log in and follow the recommended care plan instructions and events as visualized on a simple timeline. 

11/03/2015 - 10:44am

Design Rx Paks are refilled automatically every month with 28 days of prepackaged medications, Ritzman Pharmacy reported. 

11/02/2015 - 12:22pm

The New York Times is reporting that Irish pharmaceutical company Shire has entered into an agreement to purchase Dyax, a biotechnology company that makes treatements for hereditary angioedema (HAE), for as much as $6.5 billion. “This highly complementary transaction aligns with and accelerates our strategy to build a global leading biotechnology company focused on rare diseases and specialty conditions,” Shire’s CEO Dr. Flemming Ornskov said. “It adds to our portfolio of best-in-class therapies addressing unmet needs in our core therapeutic areas, expanding and extending our leadership position in HAE.” (New York Times)